NCT07016997View on ClinicalTrials.gov

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Solid TumorsRefractory Cancer
Interventions
DRUG

CBA-1535

Dosing is increased from 0.1 µg/body until DLT or disease progression occurs.

DRUG

CBA-1535+Pembrolizumab

"Drug：CBA-1535 First Dosing will be determined by Part 1. And dosing will be increased until DLT or disease progression occurs.~Drug：Pembrolizumab 200 mg/body"

Trial Locations (2)

Unknown

RECRUITING

Shizuoka Cancer Center, Nagaizumicho

RECRUITING

National Cancer Center Hospital, Chuo-Ku

Sponsors
All Listed Sponsors
lead

Chiome Bioscience Inc.

INDUSTRY